TCV-309 (chloride)

TCV-309 chloride is a potent and specific platelet activating factor (PAF) antagonist. TCV-309 chloride specifically inhibits PAF-induced aggregation of rabbit and human platelets, and [3H]PAF binding to rabbit platelet microsomes with IC50 values of 33 nM, 58 nM and 27 nM, respectively. TCV-309 chloride has beneficial effects in anaphylactic shock[1][2].

Product Specifications

CAS Number

[121494-09-5]

UNSPSC

12352005

Target

Platelet-activating Factor Receptor (PAFR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/TCV-309-chloride.html

Concentration

10mM

Purity

95.0

Solubility

DMSO : 6.3 mg/mL (ultrasonic)

Smiles

CCC[N+]1=CC(C(N(CCC(NCCOC(N2CC3=C(C=CC=C3)CC2)=O)=O)C4=CC=CC=C4)=O)=CC(Br)=C1.[Cl-]

Molecular Formula

C30H34BrClN4O4

Molecular Weight

629.97

References & Citations

[1]Terashita Z et al. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther. 1992 Feb;260 (2) :748-55.|[2]M Poeze, et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock. 2000 Oct;14 (4) :421-8.